📣 VC round data is live. Check it out!

Synergy CHC Valuation Multiples

Discover revenue and EBITDA valuation multiples for Synergy CHC and similar public comparables like Stem Cells Spin, Rain Forest International, Hemp & Health, NUTEX and more.

Synergy CHC Overview

About Synergy CHC

Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.


Founded

2010

HQ

United States

Employees

21

Financials (LTM)

Revenue: $32M
EBITDA: ($2M)

EV

$29M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Synergy CHC Financials

Synergy CHC reported last 12-month revenue of $32M and negative EBITDA of ($2M).

In the same LTM period, Synergy CHC generated $21M in gross profit, ($2M) in EBITDA losses, and had net loss of ($8M).

Revenue (LTM)


Synergy CHC P&L

In the most recent fiscal year, Synergy CHC reported revenue of $30M and EBITDA of ($6M).

Synergy CHC is unprofitable as of last fiscal year, with gross margin of 67%, EBITDA margin of (20%), and net margin of (41%).

See analyst estimates for Synergy CHC
LTMLast FY202320242025202620272028
Revenue$32M$30M$43M$35M$30M
Gross Profit$21M$20M$32M$24M$20M
Gross Margin68%67%75%68%67%
EBITDA($2M)($6M)$11M$6M($6M)
EBITDA Margin(7%)(20%)25%19%(20%)
EBIT Margin(12%)(6%)25%17%(6%)
Net Profit($8M)($12M)$6M$2M($12M)
Net Margin(24%)(41%)15%6%(41%)
Net Debt—$24M———

Financial data powered by Morningstar, Inc.

Synergy CHC Stock Performance

Synergy CHC has current market cap of $5M, and enterprise value of $29M.

Market Cap Evolution


Synergy CHC's stock price is $0.32.

Synergy CHC share price increased by 3.4% in the last 30 days, and decreased by 81.7% in the last year.

Synergy CHC has an EPS (earnings per share) of $-0.83.

See more trading valuation data for Synergy CHC
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$29M$5M0.7%3.4%-76.9%-81.7%$-0.83

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Synergy CHC Valuation Multiples

Synergy CHC trades at 0.9x EV/Revenue multiple, and (14.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Synergy CHC

EV / Revenue (LTM)


Synergy CHC Financial Valuation Multiples

As of May 5, 2026, Synergy CHC has market cap of $5M and EV of $29M.

Synergy CHC has a P/E ratio of (0.6x).

LTMLast FY202320242025202620272028
EV/Revenue0.9x1.0x0.7x0.8x1.0x
EV/EBITDA(14.1x)(4.7x)2.7x4.5x(4.7x)
EV/EBIT(7.8x)(16.1x)2.7x5.0x(16.1x)
EV/Gross Profit1.4x1.4x0.9x1.2x1.4x
P/E(0.6x)(0.4x)0.8x2.3x(0.4x)
EV/FCF—(11.2x)68.7x(6.0x)(11.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Synergy CHC Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Synergy CHC Margins & Growth Rates

In the most recent fiscal year, Synergy CHC reported gross margin of 67%, EBITDA margin of (20%), and net margin of (41%).

See estimated margins and future growth rates for Synergy CHC

Synergy CHC Margins

Last FY20242025202720282029
Gross Margin67%68%67%
EBITDA Margin(20%)19%(20%)
EBIT Margin(6%)17%(6%)
Net Margin(41%)6%(41%)
FCF Margin(9%)(14%)(9%)

Synergy CHC Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(19%)(13%)
Gross Profit Growth(26%)(14%)
EBITDA Growth(40%)(195%)
EBIT Growth(46%)(131%)
Net Profit Growth(66%)(681%)
FCF Growth(1239%)(46%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Synergy CHC Operational KPIs

Synergy CHC's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.1M for the same period.

Access forward-looking KPIs for Synergy CHC
LTMLast FY202320242025202620272028
Rule of 404%————
Bessemer Rule of X20%————
Revenue per Employee—$1.4M———
Opex per Employee—$1.1M———
S&M Expenses to Revenue40%43%36%37%43%
G&A Expenses to Revenue26%29%14%14%29%
Opex to Revenue—73%50%51%73%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Synergy CHC Competitors

Synergy CHC competitors include Stem Cells Spin, Rain Forest International, Hemp & Health, NUTEX, Enorama Pharma, 7FIT, BioRegenx, Aqua Bio Technology, Arctic Bioscience and Pharmena.

Most Synergy CHC public comparables operate across Nutraceuticals & Cosmeceuticals.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Stem Cells Spin272.8x—17.8x—
Rain Forest International————
Hemp & Health62.2x—(10.1x)—
NUTEX(4918.6x)—(4.7x)—
Enorama Pharma5.2x—(0.2x)—
7FIT0.9x—7.6x—
BioRegenx5.3x—(8.5x)—
Aqua Bio Technology1.7x—(0.6x)—

This data is available for Pro users. Sign up to see all Synergy CHC competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Synergy CHC

When was Synergy CHC founded?Synergy CHC was founded in 2010.
Where is Synergy CHC headquartered?Synergy CHC is headquartered in United States.
How many employees does Synergy CHC have?As of today, Synergy CHC has over 21 employees.
Who is the CEO of Synergy CHC?Synergy CHC's CEO is Jack Ross.
Is Synergy CHC publicly listed?Yes, Synergy CHC is a public company listed on Nasdaq.
What is the stock symbol of Synergy CHC?Synergy CHC trades under SNYR ticker.
When did Synergy CHC go public?Synergy CHC went public in 2013.
Who are competitors of Synergy CHC?Synergy CHC main competitors include Stem Cells Spin, Rain Forest International, Hemp & Health, NUTEX, Enorama Pharma, 7FIT, BioRegenx, Aqua Bio Technology, Arctic Bioscience, Pharmena.
What is the current market cap of Synergy CHC?Synergy CHC's current market cap is $5M.
What is the current revenue of Synergy CHC?Synergy CHC's last 12 months revenue is $32M.
What is the current revenue growth of Synergy CHC?Synergy CHC revenue growth (NTM/LTM) is 11%.
What is the current EV/Revenue multiple of Synergy CHC?Current revenue multiple of Synergy CHC is 0.9x.
Is Synergy CHC profitable?No, Synergy CHC is not profitable.
What is the current EBITDA of Synergy CHC?Synergy CHC has negative EBITDA and is not profitable.
What is Synergy CHC's EBITDA margin?Synergy CHC's last 12 months EBITDA margin is (7%).
What is the current EV/EBITDA multiple of Synergy CHC?Current EBITDA multiple of Synergy CHC is (14.1x).
How many companies Synergy CHC has acquired to date?Synergy CHC hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Synergy CHC has invested to date?Synergy CHC hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Synergy CHC

Lists including Synergy CHC

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial